Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645
This examiner grants 69% of resolved cases
Lakia J. Jackson-Tongue is an examiner in Tech Center 1600 and Art Unit 1645. She has 696 resolved cases. Her allowance rate is 69.0 percent, which is a favorable grant rate for applicants. This 69.0 percent figure indicates that more than two-thirds of the applications resolved by this examiner result in a patent grant, making it a productive environment for those seeking intellectual property protection.
The interview lift is 20.8 percent. This 20.8 percent lift indicates that interviews are a useful tool for increasing the probability of a grant. Practitioners should consider an interview to improve the 69.0 percent baseline allowance rate, as direct dialogue can help clarify technical issues and resolve disagreements more efficiently than written correspondence alone.
The median days to allowance is 1182. This 1182 day period is the median time to grant for successful applications. Applicants should expect a pendency of 1182 days for their cases, which reflects the typical duration of the prosecution cycle from the initial filing to the final issuance of a patent in this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18255769 | POLYMERIC NANOPARTICLE COMPOSITIONS FOR ENCAPSULATION AND SUSTAINED RELEASE OF NEUROMODULATORS | Final Rejection | The Johns Hopkins University |
| 18914188 | TREATMENT OF AUTONOMIC DISORDERS WITH BOTULINUM TOXIN | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18251657 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | Final Rejection | L'Oreal S.A |
| 18042561 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | Final Rejection | Pfizer Inc. |
| 18708530 | METHODS AND COMPOSITIONS FOR PKC-DELTA INHIBITION AND CANCER IMMUNOTHERAPY | Non-Final OA | THE UNIVERSITY OF CHICAGO |
| 18670112 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | Non-Final OA | The University of Toledo |
| 17831012 | COMPOSITIONS AND METHODS FOR THE PROPHYLAXIS AND TREATMENT OF BABESIOSIS | Non-Final OA | Tufts Medical Center, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy